Sarepta (SRPT) Lower as Marathon Pharma Receives Orphan Drug Status for Deflazacort
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Up)Join SI Premium – FREE
Sarepta Therapeutics (Nasdaq: SRPT) is on watch as the U.S. FDA approved Marathon Pharmaceutical's deflazacort as a treatment for Duchenne muscular dystrophy (DMD).
In 2010, the FDA awarded the University of Rochester Medical Center's Calcort (deflazacort) orphan drug designation and has granted around 29 such distinctions since 1983.
Orphan drugs are given seven years of market exclusivity if approved by the FDA.
Others working on a treatment for DMD include Glaxo (NYSE: GSK) and Prosensa. Shares of Sarepta are down 5.7 percent Monday.
In 2010, the FDA awarded the University of Rochester Medical Center's Calcort (deflazacort) orphan drug designation and has granted around 29 such distinctions since 1983.
Orphan drugs are given seven years of market exclusivity if approved by the FDA.
Others working on a treatment for DMD include Glaxo (NYSE: GSK) and Prosensa. Shares of Sarepta are down 5.7 percent Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) option IV flat
- AstraZeneca (AZN) enters deal with with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
- Keros Therapeutics (KROS) Presents Clinical Trial and Preclinical Study Results from its KER-050 Program
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
